Renaissance Technologies's HALO Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 1 M shares of Halozyme Therapeutics, Inc. (HALO) worth $73.36 M, representing 0.10% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 48 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in HALO, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2019, adding 760,000 shares. Largest reduction occurred in Q1 2020, reducing 895,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2013 | +300,000 | New Buy | 300,000 | $14.99 |
| Q1 2014 | -164,600 | Reduce 54.87% | 135,400 | $12.70 |
| Q2 2014 | +153,662 | Add 113.49% | 289,062 | $9.88 |
| Q3 2014 | -289,062 | Sold Out | 289,062 | $0.00 |
| Q4 2014 | +77,700 | New Buy | 77,700 | $9.65 |
| Q1 2015 | +303,100 | Add 390.09% | 380,800 | $14.28 |
| Q2 2015 | -223,200 | Reduce 58.61% | 157,600 | $22.58 |
| Q3 2015 | -146,000 | Reduce 92.64% | 11,600 | $13.45 |
| Q4 2015 | -11,600 | Sold Out | 11,600 | $0.00 |
| Q1 2016 | +375,000 | New Buy | 375,000 | $9.47 |
| Q2 2016 | -375,000 | Sold Out | 375,000 | $0.00 |
| Q3 2016 | +100,000 | New Buy | 100,000 | $12.08 |
| Q4 2016 | -85,300 | Reduce 85.30% | 14,700 | $9.86 |
| Q1 2017 | -14,700 | Sold Out | 14,700 | $0.00 |
| Q4 2017 | +736,600 | New Buy | 736,600 | $20.26 |
| Q1 2018 | +156,800 | Add 21.29% | 893,400 | $19.59 |
| Q2 2018 | -15,000 | Reduce 1.68% | 878,400 | $16.87 |
| Q3 2018 | -287,800 | Reduce 32.76% | 590,600 | $18.17 |
| Q4 2018 | -286,000 | Reduce 48.43% | 304,600 | $14.63 |
| Q1 2019 | +444,800 | Add 146.03% | 749,400 | $16.10 |
| Q2 2019 | -290,800 | Reduce 38.80% | 458,600 | $17.18 |
| Q3 2019 | -458,600 | Sold Out | 458,600 | $0.00 |
| Q4 2019 | +1.22 M | New Buy | 1.22 M | $17.73 |
| Q1 2020 | -895,200 | Reduce 73.46% | 323,400 | $17.99 |
| Q2 2020 | +684,800 | Add 211.75% | 1.01 M | $26.81 |
| Q3 2020 | -480,500 | Reduce 47.66% | 527,700 | $26.28 |
| Q4 2020 | +429 | Add 0.08% | 528,129 | $42.71 |
| Q1 2021 | +145,571 | Add 27.56% | 673,700 | $41.69 |
| Q2 2021 | -673,700 | Sold Out | 673,700 | $0.00 |
| Q3 2021 | +153,200 | New Buy | 153,200 | $40.68 |
| Q4 2021 | -27,200 | Reduce 17.75% | 126,000 | $40.21 |
| Q1 2022 | +81,700 | Add 64.84% | 207,700 | $39.88 |
| Q2 2022 | +277,500 | Add 133.61% | 485,200 | $44.00 |
| Q3 2022 | -126,900 | Reduce 26.15% | 358,300 | $39.54 |
| Q4 2022 | -216,659 | Reduce 60.47% | 141,641 | $0.06 |
| Q1 2023 | -46,500 | Reduce 32.83% | 95,141 | $0.04 |
| Q2 2023 | -61,061 | Reduce 64.18% | 34,080 | $0.04 |
| Q3 2023 | +71,600 | Add 210.09% | 105,680 | $38.20 |
| Q4 2023 | +87,700 | Add 82.99% | 193,380 | $36.96 |
| Q1 2024 | +238,000 | Add 123.07% | 431,380 | $40.68 |
| Q2 2024 | -53,800 | Reduce 12.47% | 377,580 | $52.36 |
| Q3 2024 | -122,300 | Reduce 32.39% | 255,280 | $57.24 |
| Q4 2024 | -229,170 | Reduce 89.77% | 26,110 | $47.81 |
| Q1 2025 | +93,900 | Add 359.63% | 120,010 | $63.81 |
| Q2 2025 | +218,599 | Add 182.15% | 338,609 | $52.02 |
| Q3 2025 | +661,600 | Add 195.39% | 1 M | $73.34 |
Renaissance Technologies's Halozyme Therapeutics Investment FAQs
Renaissance Technologies first purchased Halozyme Therapeutics, Inc. (HALO) in Q4 2013, acquiring 300,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Halozyme Therapeutics, Inc. (HALO) for 48 quarters since Q4 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q4 2019, adding 1,218,600 shares worth $21.61 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 1,000,209 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $73.36 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.10% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in Halozyme Therapeutics, Inc. (HALO) was 1,218,600 shares, as reported at the end of Q4 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.